# IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct07483554/  
OnCo record `nct07483554` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IBI343, Gemcitabine in pancreatic ductal adenocarcinoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors is a phase 2 interventional study registered as NCT07483554 by Innovent Biologics (Suzhou) Co. Ltd., with 389 participants planned, started 2026-04-20 and due to reach its primary completion in 2028-03-31. Interventions recorded: IBI343,Gemcitabine, Albumin-bound Paclitaxel. Conditions listed: CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07483554
- Phase: 2
- Setting: A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 389

## Sources

- ClinicalTrials.gov NCT07483554: https://clinicaltrials.gov/study/NCT07483554

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [IBI343](https://onco.cc/drugs/ibi343/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/nct07483554.json